Synthetic cell mimic products launched for flow cytometry controls

Amsbio has launched a range of synthetic cell mimic products that eliminate the variability, fragility and operational inefficiency inherent in traditional flow cytometry biological and polystyrene bead controls.

Researchers in pharmaceutical companies, biotechnology firms, contract research organisations (CROs), clinical diagnostics and academic centres have long sought access to mass‑produced cell mimics that contain rare biomarkers and are stable over the long term for the development of targeted therapies.

Benefitting from unmatched lot-to-lot consistency with coefficients of variation as low as 0.1 per cent, these new synthetic cell-mimic controls enable researchers to achieve reproducible results across multiple sites and instruments. This consistency is a critical requirement for clinical trials, cell therapy manufacturing and rapid, successful regulatory submissions.

For laboratory teams running flow cytometry assays across instruments, operators and sites, Amsbio can now offer cell-mimic controls that deliver biology-like behaviour without the variability of donor peripheral blood mononuclear cells (PBMCs), the safety burden of biohazardous materials, or the maintenance overhead of cell lines. This helps researchers standardise workflows, tighten assay performance and reduce bridging studies. Offering extended shelf life with no maintenance required, synthetic cell mimics from Amsbio are fully customisable with biomarkers, proteins and fluorescence, making them perfect for any need.

Amsbio, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research, and cell and gene therapy across Europe, North America and wider international markets. With in-depth expertise in advanced cell culture, three-dimensional (3D) cell models and cryopreservation, Amsbio is well placed to help researchers progress from early discovery through to clinical and Good Manufacturing Practice (GMP)-ready applications. 

The company's portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development and disease modelling, through to stem cell and organoid-based research. Key solutions include the integrated stem cell platform combining StemFit™ media, iMatrix™ recombinant laminins and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services including viral delivery. 

Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, Amsbio is internationally recognised for delivering high-quality, application-ready products and services. Amsbio has a consistent record of close scientific collaboration with partners in academic, biotech and pharmaceutical markets to translate innovation from bench to bedside.